Emmaus Life Sciences Announces Opening of Office in New York to Support Endari Launch Mar 26, 2018 8:00am EDT
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine) Mar 12, 2018 8:00am EDT
Emmaus Life Sciences Announces Medicaid Coverage of Endari™ (L-glutamine oral powder) for Sickle Cell Disease in the United States Jan 29, 2018 8:00am EST
Emmaus Life Sciences Announces Availability of Endari™ (L-glutamine oral powder) for Sickle Cell Disease in the United States Jan 17, 2018 9:00am EST
Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency Dec 21, 2017 7:22pm EST
Emmaus Medical, Inc. Announces Availability of Endari™ for Treatment of Sickle Cell Disease Dec 11, 2017 9:00am EST
Emmaus Life Sciences, Inc. to Present Results of Phase 3 Study of EndariTM (L-glutamine oral powder) at 59th American Society of Hematology Annual Meeting Nov 28, 2017 9:00am EST
The U.S. Food & Drug Administration Approves Endari™ (L-glutamine oral powder), the First and Only Treatment for Sickle Cell Disease in Pediatric Patients and First in Nearly 20 Years for Adults Jul 07, 2017 3:57pm EDT
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell Disease May 24, 2017 5:43pm EDT
